NASDAQ: BMRN | Healthcare / Biotechnology / USA |
95.03 | -1.91 | -1.97% | Vol 711.92K | 1Y Perf 29.08% |
Aug 16th, 2022 16:00 DELAYED |
BID | 92.77 | ASK | 98.00 | ||
Open | 97.00 | Previous Close | 96.94 | ||
Pre-Market | - | After-Market | 95.06 | ||
- - | 0.03 0.03% |
Target Price | 111.23 | Analyst Rating | Strong Buy 1.32 | |
Potential % | 17.05 | Finscreener Ranking | ★★★★ 53.94 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★+ 50.00 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★★ 57.26 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 89.90 | Earnings Rating | Sell | |
Market Cap | 17.63B | Earnings Date | 3rd Aug 2022 | |
Alpha | -0.00 | Standard Deviation | 0.08 | |
Beta | 0.33 |
Today's Price Range 94.7797.00 | 52W Range 70.7397.76 | 5 Year PE Ratio Range -487.5020.80 |
Summary:
Buy
Technical Indicators: | Neutral |
Moving Averages: | Strong Buy |
Performance | |||
---|---|---|---|
1 Week | -1.01% | ||
1 Month | 9.13% | ||
3 Months | 20.11% | ||
6 Months | 5.24% | ||
1 Year | 29.08% | ||
3 Years | 24.22% | ||
5 Years | 17.35% | ||
10 Years | 150.41% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 4.67 | |||
ROE last 12 Months | 1.24 | |||
ROA (5Y Avg) | 2.60 | |||
ROA last 12 Months | 0.90 | |||
ROC (5Y Avg) | 2.56 | |||
ROC last 12 Months | 1.11 | |||
Return on invested Capital Q | 0.52 | |||
Return on invested Capital Y | -1.06 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 1.80 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
365.70 | ||||
3.91 | ||||
9.41 | ||||
148.40 | ||||
-4 013.00 | ||||
0.64 | ||||
4.48 | ||||
24.29 | ||||
17.61B | ||||
Forward PE | 36.84 | |||
PEG | 7.26 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
3.40 | ||||
5.40 | ||||
0.19 | ||||
0.24 | ||||
4.80 | ||||
Leverage Ratio | 1.40 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
75.80 | ||||
3.70 | ||||
9.20 | ||||
-8.30 | ||||
2.83 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.91B | ||||
10.31 | ||||
5.88 | ||||
9.42 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2022 | 0.20 | 0.33 | 65.00 |
Q01 2022 | 0.15 | 0.31 | 106.67 |
Q04 2021 | -0.22 | -0.21 | 4.55 |
Q03 2021 | -0.12 | -0.03 | 75.00 |
Q02 2021 | 0.05 | 0.23 | 360.00 |
Q01 2021 | 0.07 | 0.29 | 314.29 |
Q04 2020 | -0.06 | -0.05 | 16.67 |
Q03 2020 | -0.01 | 0.29 | 3.00K |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | 0.20 | -33.33 | Negative |
9/2022 QR | 0.15 | -25.00 | Negative |
12/2022 FY | 0.95 | 6.74 | Positive |
12/2023 FY | 2.58 | -3.37 | Negative |
Next Report Date | - |
Estimated EPS Next Report | 0.20 |
Estimates Count | 8 |
EPS Growth Next 5 Years % | 50.40 |
Volume Overview | |
---|---|
Volume | 711.92K |
Shares Outstanding | 185.47K |
Shares Float | 184.17M |
Trades Count | 12.19K |
Dollar Volume | 68.04M |
Avg. Volume | 1.10M |
Avg. Weekly Volume | 1.12M |
Avg. Monthly Volume | 1.06M |
Avg. Quarterly Volume | 1.13M |
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) stock closed at 95.03 per share at the end of the most recent trading day (a -1.97% change compared to the prior day closing price) with a volume of 711.92K shares and market capitalization of 17.63B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 3059 people. BioMarin Pharmaceutical Inc. CEO is Jean-Jacques Bienaime.
The one-year performance of BioMarin Pharmaceutical Inc. stock is 29.08%, while year-to-date (YTD) performance is 7.56%. BMRN stock has a five-year performance of 17.35%. Its 52-week range is between 70.73 and 97.76, which gives BMRN stock a 52-week price range ratio of 89.90%
BioMarin Pharmaceutical Inc. currently has a PE ratio of 365.70, a price-to-book (PB) ratio of 3.91, a price-to-sale (PS) ratio of 9.41, a price to cashflow ratio of 148.40, a PEG ratio of 2.32, a ROA of 0.90%, a ROC of 1.11% and a ROE of 1.24%. The company’s profit margin is 2.83%, its EBITDA margin is 9.20%, and its revenue ttm is $1.91 Billion , which makes it $10.31 revenue per share.
Of the last four earnings reports from BioMarin Pharmaceutical Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.20 for the next earnings report. BioMarin Pharmaceutical Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for BioMarin Pharmaceutical Inc. is Strong Buy (1.32), with a target price of $111.23, which is +17.05% compared to the current price. The earnings rating for BioMarin Pharmaceutical Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BioMarin Pharmaceutical Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BioMarin Pharmaceutical Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 14.57, ATR14 : 2.45, CCI20 : 98.82, Chaikin Money Flow : 0.18, MACD : 3.23, Money Flow Index : 68.74, ROC : 11.32, RSI : 72.42, STOCH (14,3) : 93.73, STOCH RSI : 0.88, UO : 62.34, Williams %R : -6.27), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BioMarin Pharmaceutical Inc. in the last 12-months were: Brian Mueller (Sold 0 shares of value $-237 335 ), Brian Mueller (Sold 10 837 shares of value $987 412 ), Charles Greg Guyer (Sold 6 205 shares of value $599 155 ), Dennis J. Slamon (Sold 6 296 shares of value $493 178 ), Elaine J. Heron (Sold 0 shares of value $-318 410 ), G. Eric Davis (Sold 0 shares of value $-4 572 497 ), G. Eric Davis (Sold 101 566 shares of value $9 044 118 ), Jean-Jacques Bienaime (Sold 0 shares of value $-4 345 360 ), Jean-Jacques Bienaime (Sold 116 500 shares of value $9 483 282 ), Jeffrey R. Ajer (Sold 16 428 shares of value $1 309 691 ), Richard A. Meier (Sold 0 shares of value $-318 410 ), Richard A. Meier (Sold 3 878 shares of value $318 345 ), V. Bryan Lawlis (Sold 0 shares of value $-318 410 ), V. Bryan Lawlis (Sold 8 500 shares of value $727 898 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.
CEO: Jean-Jacques Bienaime
Telephone: +1 415 506-6700
Address: 770 Lindaro Street, San Rafael 94901, CA, US
Number of employees: 3 059
Fri, 12 Aug 2022 09:04 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Arbutus Biopharma (ABUS), BioMarin Pharmaceutical (BMRN) and Enovis (ENOV)
- TipRanks. All rights reserved.Thu, 04 Aug 2022 16:43 GMT Morgan Stanley Believes BioMarin Pharmaceutical (BMRN) Still Has Room to Grow
- TipRanks. All rights reserved.Mon, 25 Jul 2022 09:22 GMT BioMarin Pharmaceutical (BMRN) Receives a Buy from SVB Securities
- TipRanks. All rights reserved.Fri, 22 Jul 2022 03:45 GMT Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Illumina (ILMN) and Ionis Pharmaceuticals (IONS)
- TipRanks. All rights reserved.Wed, 13 Jul 2022 18:55 GMT BioMarin Pharmaceutical (BMRN) Gets a Hold Rating from Wedbush
- TipRanks. All rights reserved.Mon, 13 Jun 2022 11:15 GMT Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Medicinova (MNOV)
- TipRanks. All rights reserved.Tue, 31 May 2022 17:25 GMT BioMarin Pharmaceutical (BMRN) Received its Third Buy in a Row
- TipRanks. All rights reserved.Fri, 20 May 2022 03:55 GMT Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Thermo Fisher (TMO) and Atreca (BCEL)
- TipRanks. All rights reserved.Sat, 30 Apr 2022 01:46 GMT BioMarin Pharmaceutical (BMRN) Receives a Hold from RBC Capital
- TipRanks. All rights reserved.Thu, 28 Apr 2022 10:45 GMT Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Sanofi (OtherSNYNF)
- TipRanks. All rights reserved.Sat, 26 Feb 2022 15:55 GMT BioMarin Pharmaceutical (BMRN) Gets a Buy Rating from Robert W. Baird
- TipRanks. All rights reserved.Mon, 10 Jan 2022 14:05 GMT Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Icosavax (ICVX)
- TipRanks. All rights reserved.Mon, 10 Jan 2022 13:55 GMT Analysts Top Healthcare Picks: BioMarin Pharmaceutical (BMRN), Autolus Therapeutics (AUTL)
- TipRanks. All rights reserved.Thu, 06 Jan 2022 14:05 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: BioMarin Pharmaceutical (BMRN), Illumina (ILMN) and Catalent (CTLT)
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.